Moderna (MRNA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
6 May, 2026Opening remarks and agenda
Chairman welcomed attendees, introduced board members and executives, and outlined the meeting agenda.
Formal business included four proposals: election of directors, advisory vote on executive compensation, advisory vote on frequency of compensation votes, and ratification of the accounting firm.
Board and executive committee updates
Board members and executive committee were introduced, with some attending virtually.
Inspector of Election and meeting secretary roles were formally established.
Corporate governance
Shareholder list and meeting materials were made available in accordance with legal requirements.
Quorum was confirmed, allowing official business to proceed.
Voting procedures were explained, including proxy and virtual ballot options.
Latest events from Moderna
- Q1 2026 revenue surged 260% but net loss deepened to $1.3B due to a major litigation settlement.MRNA
Q1 20264 May 2026 - Up to 10% revenue growth in 2026 driven by late-stage pipeline, cost discipline, and expansion.MRNA
44th Annual J.P. Morgan Healthcare Conference12 Apr 2026 - Proxy covers director elections, pay, auditor ratification, and robust cost savings in 2025.MRNA
Proxy Filing16 Mar 2026 - Key votes include director elections, executive pay, and auditor ratification for 2026.MRNA
Proxy Filing16 Mar 2026 - Guiding up to 10% revenue growth in 2026, driven by global partnerships and pipeline progress.MRNA
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Strong vaccine performance and pipeline diversification drive growth and future profitability.MRNA
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - 2025 saw $1.9B revenue, cost cuts, and pipeline gains; 2026 targets 10% growth.MRNA
Q4 202513 Feb 2026 - Q2 2024 revenue was $241M, net loss $1.3B, and 2024 sales guidance is $3.0–$3.5B.MRNA
Q2 20242 Feb 2026 - Strong phase III data and strategic partnerships drive pipeline progress in vaccines and oncology.MRNA
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026